SHAREHOLDER ACTION ALERT: Schall Law Firm Encourages Investors in Homology Medicines, Inc. with $100,000 Losses to Contact Firm

LOS ANGELES–(BUSINESS WIRE)–The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Homology Medicines, Inc. (“Homology” or “the Company”) (NASDAQ: FIXX) for violation of §§ 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the United States Securities and Exchange Commission.

Investors who purchased the Company’s securities between June 10, 2019 and February 18, 2022 inclusive (the “Class Period”) are invited to contact the Company before May 24, 2022.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com or by email at [email protected]

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to do nothing, you can remain an absent member of the group.

According to the complaint, the company made false and misleading statements to the market. The homology has inflated the efficacy and risk mitigation of its gene therapy product candidate, HMI-102. In fact, the Company was unlikely to be able to commercialize gene therapy in its current form. Based on these facts, the Company’s public statements were false and materially misleading throughout the Class Period. When the market learned the truth about homology, investors suffered damage.

Join the case to recoup your losses.

Schall Law Firm represents investors worldwide and specializes in securities class action and shareholder rights litigation.

This press release may be considered attorney advertising in certain jurisdictions under applicable law and ethics rules.